Natera, Inc. (NASDAQ:NTRA) CEO Sells $233,201.76 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,552 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76. Following the transaction, the chief executive officer now owns 230,319 shares in the company, valued at $21,046,550.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The shares were sold at an average price of $93.13, for a total transaction of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The shares were sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $964,178.17.

Natera Trading Up 2.7 %

Shares of NTRA opened at $91.04 on Wednesday. The stock has a market capitalization of $10.99 billion, a P/E ratio of -24.02 and a beta of 1.37. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The firm has a fifty day simple moving average of $86.40 and a two-hundred day simple moving average of $66.49. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. On average, research analysts anticipate that Natera, Inc. will post -2.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their target price for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Piper Sandler upped their price target on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Canaccord Genuity Group upped their price target on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. BTIG Research upped their price target on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Finally, Stephens restated an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently modified their holdings of NTRA. National Bank of Canada FI purchased a new stake in shares of Natera in the 3rd quarter worth about $1,932,000. CWM LLC increased its stake in shares of Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after acquiring an additional 911 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Natera by 1,503.2% in the 3rd quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock worth $4,335,000 after acquiring an additional 91,862 shares in the last quarter. Ellsworth Advisors LLC bought a new position in shares of Natera in the 3rd quarter worth about $364,000. Finally, Xponance Inc. increased its stake in shares of Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after acquiring an additional 261 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.